This study explored the therapeutic potential of tirzepatide, a dual glucagon-like peptide-1 receptor (GLP-1R)/glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist, in preclinical models of AUD, while elucidating the neurobiological mechanisms mediating its effects. Our methodologica...
Tirzepatide is an anti-obesity drug based on dual agonism of the incretin receptors GLP-1R and GIPR. Its anti-obesity effect is largely based on its action of reducing food intake. However, there are suggestive indications that tirzeparide may exert effects on adipose tissues beyond those resulting ...
Tirzepatide (LY3298176), a dual GIP and GLP-1 receptor agonist, has been shown to deliver enhanced glycemic control and superior weight loss compared to a selective GLP-1 receptor (GLP-1R) agonist in patients with type 2 diabetes mellitus. However, the mechanism by which tirzepatide improves efficac...
Effects of Tirzepatide on macrophage polarization, inflammatory factors and atherosclerotic genes in RAW264.7 cells under oxidative low-density lipoprotein
This study investigates spatial gene expression changes in rat gut tissue under different dietary and treatment conditions using 10x Genomics Visium spatial transcriptomics. Four experimental groups were analyzed: control diet with PBS treatment (CD_PBS), control diet with tirzepatide treatment (CD_...
